[Results of chemotherapy in patients with disseminated testicular tumors].

Results of treatment of 44 patients with disseminated non-seminomatous testicular tumors versus advancement are discussed in the paper. In cases of minimal and moderate advancement (group 1), induction chemotherapy included three cycles of VAB-6 regimen (vinblastine, actinomycin D, bleomycetin, cyclophosphamide plus 120 mg/m2 platidiam) whereas cases of advanced tumor (group 2) received six such cycles; two of them used 150 mg/m2 platidiam dropwise in a 3% sodium chloride solution. Complete regression was observed in 22 of 24 (96.1%) patients of group 1 and in seven out of 20 (35%) cases of group 2; it was registered in 100, 81.8 and 38% of patients with minimal, moderately- and far-advanced disease, respectively. Patients were followed for 4-23 months (average 14.5 months). Eight cases relapsed. At the time of this writing, 38 out of 44 (86.3%) patients are alive, and 23 out of 29 (79.3%) continue in complete remission. Toxicity was moderate. Application of 3% NaCl prevented nephrotoxicity of high-dose (150 mg/m2) platidiam.